Icatibant Newbury

Icatibant, the active ingredient in Icatibant Newbury, is a bradykinin B2 receptor antagonist presented as a subcutaneous formulation for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with confirmed HAE. GNH USA supplies Icatibant Newbury as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a targeted therapy for bradykinin‑mediated angioedema conditions. - Acute hereditary angioedema (HAE) attacks: provides rapid relief of swelling and associated symptoms. - Hereditary angioedema type I and II: reduces frequency and severity of episodic attacks. - Bradykinin‑mediated angioedema (non‑HAE): helps control swelling when bradykinin is the primary mediator.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin irritation. - Swelling at injection site: transient edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, pruritus, or anaphylaxis. - Severe hypotension: marked drop in blood pressure. - Angioedema unrelated to HAE: unexpected swelling. - Urticaria: hives or wheals. - Injection site necrosis: tissue damage at the site. - Severe abdominal pain: persistent or worsening abdominal discomfort.

Before using Icatibant, consider the following safety measures. - Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: use with caution; potential exposure to the infant is unknown. - Renal impairment: dose adjustment may be required; monitor renal function. - Concomitant ACE inhibitors or ARBs: increased risk of angioedema; assess benefit‑risk. - Known hypersensitivity: avoid if allergic to icatibant or any excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - ACE inhibitors: heightened risk of angioedema; avoid concurrent use. - Angiotensin receptor blockers (ARBs): may increase angioedema risk; avoid. - Other bradykinin B2 antagonists: additive pharmacologic effect; avoid. - C1‑esterase inhibitor concentrates: potential interference with therapeutic effect; avoid.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may modify HAE severity; monitor. - Diuretics: can affect fluid balance; observe for hypotension. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate angioedema; monitor closely.